Menopause Before 40: 22.6% Got High Blood Pressure, vs 16.6%

Premature menopause usually arrives framed as a fertility problem. A woman in her thirties is told her ovaries have stopped, the conversation turns to whether she wanted children and whether she still might, and the appointment ends there. What rarely follows is a sentence about her arteries.

A cohort study published on July 29 in Menopause, the journal of The Menopause Society, argues that such a sentence belongs in that appointment. Across 107,836 postmenopausal women in the UK Biobank, the earlier menopause arrived, the more likely a woman was to be diagnosed with high blood pressure over the following decade and a half. The peak of that curve, the authors report, sits well below the age-40 line that defines the word premature.

Every figure here comes from the society's press release. The published paper was not publicly retrievable at the time of writing — the DOI it carries does not yet resolve — so nothing in this account has been checked against the article's own tables.

The UK Biobank enrolled its participants between 2006 and 2010 and has followed them since; this analysis ran through the end of 2023, a median of nearly fifteen years. The researchers sorted women into three groups by the age menopause occurred — after 45, which they treated as normal; 40 to 45, which they called early; and before 40, which is premature — and separately noted whether menopause was natural or surgical. The outcome was a new hypertension diagnosis during follow-up.

By the end, 18,508 women — 17.2 percent of the cohort — had been diagnosed. The gradient across the three groups is the study's central image. Among women whose menopause came after 45, 16.6 percent developed hypertension. Among the early group, 18.8 percent. Among women who reached menopause before 40, 22.6 percent.

Modeled on a continuous scale rather than in bands, the risk did not peak at 40. It peaked, the researchers found, among women whose menopause came between 25 and 35 — meaning the clinical cutoff that names the condition falls somewhere down the slope rather than at its top. Stephanie Faubion, medical director of The Menopause Society, said the results "highlight the potential adverse long-term health outcomes associated with premature menopause," and the authors' recommendation follows from that: treat age at menopause as a cardiovascular risk factor in its own right, and start looking for high blood pressure earlier in women who reached it before 40.

The 16.6-to-22.6 spread is the number that traveled, and it is a crude comparison — six percentage points between two groups of women who differ in far more than the age their periods stopped. The researchers then adjusted for more than fifty variables, including weight, lifestyle habits, family history and laboratory results. What survived was a 12.3 percent higher relative risk of hypertension for premature menopause. Applied to a 16.6 percent baseline, that is roughly two percentage points of absolute excess, not six. That conversion is itself approximate — the adjusted model's reference rate is not the crude 16.6 percent — but it is the only arithmetic the released figures permit. Both figures are in the same press release; only one of them made the headlines.

Which of those two numbers is closer to the truth is genuinely unsettled, and not in the direction the usual disclaimer suggests. Nearly all of those covariates were measured when the women enrolled, between 2006 and 2010 — years or decades after menopause for essentially everyone in the premature group. If early ovarian failure contributes to weight gain and metabolic drift, and those in turn raise blood pressure, then adjusting for weight and laboratory values at enrolment subtracts part of the very pathway under investigation. The adjusted estimate may understate the association as easily as the crude one overstates it. Neither figure is reported with a confidence interval in the released findings, so how precisely either is pinned down cannot be judged from the outside.

One more measurement problem sits underneath everything. Age at menopause in the UK Biobank is self-reported at enrolment. A woman who joined at 60 and whose menopause came at 33 was recalling an event from twenty-seven years earlier — and recall of that kind is neither perfectly accurate nor plausibly random with respect to later illness.

Buried in the same release is the finding that most complicates the story. Surgical menopause — ovaries removed on a datable morning — is the cleanest available version of the hypothesis that abrupt estrogen loss drives blood pressure upward. Women who went through it did show higher crude rates of hypertension. But that association, the researchers report, did not hold once other risk factors were accounted for.

The release reads this as confounding: women who have their ovaries removed differ from women who do not, in ways that also predict hypertension. That is a reasonable interpretation. It is also, read the other way, the sharpest test of the hormone mechanism in the paper, and it did not survive adjustment. A finding that survives adjustment when menopause is classified by the age it arrived, but vanishes when it is classified as surgical, is not a clean story about estrogen. The release does not report the age-band estimate split by natural versus surgical menopause, so how much of the 12.3 percent the natural cases carry cannot be read from the outside. It is an invitation to ask what else travels with an early natural menopause — genetics, smoking history, childhood adversity, chronic illness — that a surgical one does not carry.

Two percentage points spread over fifteen years is not a number that should frighten anyone, and the study cannot establish that early menopause causes hypertension. But the intervention on offer is not a drug. It is a blood pressure cuff, applied earlier and more often to a group of women for whom routine blood-pressure screening currently runs on the slow setting — every three to five years before 40, annually only after, unless something already marks them as higher-risk. What the study argues is that an early menopause is that mark. Hypertension is common, silent, cheap to detect and treatable; the asymmetry between the cost of looking and the cost of missing it does most of the work here, and an imprecise association is enough to justify looking.

One clarification the coverage tended to blur: the release also quotes The Menopause Society's standing guidance that hormone therapy is routinely recommended in women with premature menopause at least until the natural age of menopause, absent contraindications. That is society guidance of long standing. It is not a result of this study, which as reported did not test whether hormone therapy altered the hypertension association at all.

There is a particular kind of study that is right about the direction and unhelpful about the size, and this is one of them. The gradient is real and orderly — 16.6, 18.8, 22.6 percent, exactly the shape a dose-response relationship makes — and it survives an unusually heavy adjustment. What the coverage did was quote the crude six-point gap as though it were the finding, when the study's own adjusted estimate implies something closer to two points, and the surgical-menopause result, which did not survive adjustment and cuts against the tidy estrogen explanation, went almost entirely unmentioned. The defensible reading is narrower than the headlines and still worth acting on: age at menopause carries information about cardiovascular risk that current screening schedules do not use, and for a woman whose periods stopped at 34, the case for moving her into the annual-check tier ahead of what her age alone would trigger does not require the causal question to be settled first. — Gale Staff